Abstract: In order to stabilize solutions of human albumin for therapeutic use for the purpose of their treatment by heat in a container, in particular in the final container, there is added, in addition to the usual stabilizing formula, a surfactant agent selected from among Tween 80, Tween 20, Pluronic F68, laurate of polyethylene glycol 600 or any other equivalent agent.

Abstract: The subject of the invention is a procedure for the preparation of water-soluble macromolecular conjugates of hemoglobin, characterized in that:in the first step, Z sites are bound to a polymer P, the Z sites containing, on the one hand, at least one negative charge borne for example by sulfate groups and intended to lead to the formation of an ionic linkage with hemoglobin, and containing, on the other hand, at least one carboxylic group for example intended to lead to the formation of a covalent linkage with hemoglobin,then in the second step, the polymer P containing the Z site(s) is made to react with hemoglobin in the oxygenated form in order to form, on the one hand, at least one ionic linkage between at least one of the Z sites borne by the polymer and hemoglobin and, on the other hand, at least one covalent linkage between the same Z site mentioned above borne by the polymer and hemoglobin.

Abstract: A process for stabilizing attenuated lyophilized vaccines with a compound having the general formula: ##STR1## wherein R1 is an oxygen atom or a sulphur atom and R2 is a NH.sub.2 group or a linear chain, unsaturated or not, selected from the group consisting of --O--C . . . , --NH--C . . . , and --C . . . .

Abstract: A chromatography material comprises a solid support on which is fixed, as a ligand, desialyled gycolprotein selected from desialyled fetuin and desialyled haptoglobin. This material is used to purify protein antigens of bacteria of the Bordetella genus.

Abstract: A culture medium composition for bacteria of the Bordetella genus comprises a nutrient medium containing cyclodextrin or a salt thereof in combination with an etherified derivative of D-glucose polymer having a molecular mass at least equal to 2,000. A process for culturing bacteria of the Bordetella genus with such a medium is also disclosed.

Abstract: Collagen is submitted to a controlled oxidation by treatment with a solution of periodic acid or of a periodate, notably of sodium. Application to gels, implants, lenses, films, spheres, etc., of collagen.

Abstract: Recombinant herpes viruses useful as effective ingredients in vaccines against both virulent HSV-1 and HSV-2 are disclosed. Methods of preparing the recombinant viruses, vaccines incorporating the viruses, and methods of immunizing a human host by inoculation with the vaccines are also disclosed.The genomes of the recombinant viruses each comprise a mutant of the HSV-1 genome from which a portion thereof responsible for neurovirulence yet nonessential for growth is deleted. A gene from the HSV-2 genome responsible for coding an immunity-inducing glycoprotein is inserted in the mutant genome between the end points of deletion therein.

Abstract: A method for the purification, solubilization and/or detoxification of protein antigens of bacteria of the Bordetella genus involves the use of a carbonate buffer having a pH of 8.3 to 11.6. An acellular anti-whooping cough vaccine containing active principles in this carbonate buffer is also disclosed.

Abstract: The process comprises subjecting the hemolyzed blood to a clarification step at a pH of between 4 and 6 in the presence of less than 15% of alcohol, then, after concentration, effecting a chromatography by exchange of anions so as to separate the hemoglobin, the albumin being thereafter eluted. The hemoglobin and the globulins may then be separated out by precipitation with 25% alcohol at a pH of 7. The proteins obtained are in the native state.

Abstract: This medication consists of Fc fragments of human IgG, or of analogues of said fragments, and [is characterized by the fact] that it is free of intact IgG and/or Fab fragments or contains no more than 2% by weight of the latter with respect to total weight (Fc+Fab+IgG), it being understood that said analogues of Fc fragments of human IgG are all fragments or subfragments of Fc and all synthetic or semisynthetic peptides containing peptide sequences present in the Fc fragment, as well as all derivatives of these fragments, subfragments, or peptides, provided that these fragments, subfragments, peptides, or derivatives fulfill the following conditions:they have properties that activate the differentiation of suppressive cells;they have properties that inhibit antibody-dependent cytotoxicity;they do not have properties that activate NK cells.

Abstract: Process for the preparation in a series of self-injectable syringes characterized mainly by the fact that multiple seal tubes are placed vertically on an appropriate support, that a syringe body is placed vertically in each seal tube, that, into each tubular body thus arranged, a single dose of the medication in solution in a solvent is placed in each seal tube, above the syringe body, a plunger suspended by its pusher in a movable manner, at the lower end of a stopper which can adapt to the seal tube, so that said plunger is essentially in the axis of the syringe body and the lower end of said plunger is located above the upper end of the syringe body, with said stopper being held in a position so that said seal tube is not blocked or is not entirely blocked, to thus obtain an assembly constituting an open system in which the internal space, in the seal tubes and above said solution in the syringe bodies, is connected with the outside of the system, that the lyophilization operation is effected and, at this

Abstract: A novel subunit vaccine employing glycoprotein A of human cytomegalovirus or fragments thereof is provided. The vaccine is particularly suitable for inoculation of immunosuppressed individuals and women of childbearing age to inhibit the transmission of hCMV to the fetus.

Abstract: The plasma proteins contained in a plasma solution thereof are chromatographically fractioned, e.g., to obtain a high purity therapeutic grade albumin product, by successively contacting said plasma solution with at least one anion exchanger and at least one cation exchanger in fixed bed chromatography columns, the contact and exchange medium of chromatography therein also comprising a plurality of at least partially hydrophobic support particulates and a plurality of hydrophilic ion exchanger support particulates.

Abstract: A porous mineral support such as a porous mineral oxide coated with an aminated polysaccharide polymer has cationic characteristics and is capable of reversibly fixing thereto biological macromolecules. This material is employed in the separation and purification of said biologic maromolecules.

Abstract: A live viral vaccine against herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) incorporates as an effective ingredient at least one intertypic (HSV-1.times.HSV-2) vaccinal recombinant virus strain.

Abstract: An 80% alcoholic solution of haemoglobin having a pH close to 3 is adsorbed on active charcoal at less than 20.degree. C. while continuously stirring and the globin solution obtained is separated out by centrifuging or filtering. The globin obtained is depigmented.

Abstract: A new vaccine against viral NANB hepatitis containing NANBs antigen in a physiologically acceptable medium. The vaccine is prepared by selecting serums or plasmas in which the presence of NANBs antigens has been identified and thereafter purifying the said antigens. Antibodies are also set forth.

Abstract: Procedure for the preparation of a concentrate of prothrombinogenic compound.This procedure, in which, starting from a source of prothrombinogenic compound, an adsorption is followed by an elution, is characterized by the fact that a source of prothrombinogenic compound and a source of antithrombin III (or AT III) is placed in contact with an adsorbing agent capable of adsorbing both the prothrombinogenic compound and antithrombin III, and that the foregoing occurs in the presence of heparin, at least during the elution stage, and that elution is carried out with an elution agent capable of eluting the prothrombinogenic compound, the AT III and heparin at the same time.Application of the product obtained, notably to the treatment of blood coagulation difficulties.

Abstract: An improved packaging and assembly is provided for a multiple-point sacrifying device for vaccinating or skin testing. In order to insure economic wage of immunological or allergenic liquid pre-assembled on the scarifying device, each cluster of multiple points is assembled with a removable surrounding envelope that achieves a hermetic seal with its mounting and which presents a transverse annual attachment wall to which an envelope-closing lid is hermetically secured after a limited quantity of liquid is deposited into the limited volume chamber surrounded by the envelope.